Literature DB >> 12370421

Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.

Ume L Abbas1, John W Mellors.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12370421      PMCID： PMC129679          DOI： 10.1073/pnas.212518999

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  27 in total

1.  Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression.

Authors:  H Hatano; S Vogel; C Yoder; J A Metcalf; R Dewar; R T Davey; M A Polis
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

2.  Immune control of HIV-1 after early treatment of acute infection.

Authors:  E S Rosenberg; M Altfeld; S H Poon; M N Phillips; B M Wilkes; R L Eldridge; G K Robbins; R T D'Aquila; P J Goulder; B D Walker
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

3.  Control of SIV rebound through structured treatment interruptions during early infection.

Authors:  F Lori; M G Lewis; J Xu; G Varga; D E Zinn; C Crabbs; W Wagner; J Greenhouse; P Silvera; J Yalley-Ogunro; C Tinelli; J Lisziewicz
Journal:  Science       Date:  2000-11-24       Impact factor: 47.728

4.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.

Authors:  R T Davey; N Bhat; C Yoder; T W Chun; J A Metcalf; R Dewar; V Natarajan; R A Lempicki; J W Adelsberger; K D Miller; J A Kovacs; M A Polis; R E Walker; J Falloon; H Masur; D Gee; M Baseler; D S Dimitrov; A S Fauci; H C Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

5.  Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption.

Authors:  E Papasavvas; G M Ortiz; R Gross; J Sun; E C Moore; J J Heymann; M Moonis; J K Sandberg; L A Drohan; B Gallagher; J Shull; D F Nixon; J R Kostman; L J Montaner
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

Review 6.  Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.

Authors:  J M Kilby; P A Goepfert; A P Miller; J W Gnann; M Sillers; M S Saag; R P Bucy
Journal:  Ann Intern Med       Date:  2000-09-19       Impact factor: 25.391

7.  Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection.

Authors:  S Bonhoeffer; M Rembiszewski; G M Ortiz; D F Nixon
Journal:  AIDS       Date:  2000-10-20       Impact factor: 4.177

8.  Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy.

Authors:  P A Haslett; D F Nixon; Z Shen; M Larsson; W I Cox; R Manandhar; S M Donahoe; G Kaplan
Journal:  J Infect Dis       Date:  2000-04-05       Impact factor: 5.226

9.  Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency.

Authors:  C R Rinaldo; X L Huang; Z Fan; J B Margolick; L Borowski; A Hoji; C Kalinyak; D K McMahon; S A Riddler; W H Hildebrand; R B Day; J W Mellors
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

10.  CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection.

Authors:  M Matloubian; R J Concepcion; R Ahmed
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103
View more
  7 in total

1.  Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.

Authors:  Koen K A Van Rompay; Raman P Singh; Walid Heneine; Jeffrey A Johnson; David C Montefiori; Norbert Bischofberger; Marta L Marthas
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 2.  HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.

Authors:  Viviana Simon; David D Ho; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

Review 3.  The dual impact of antiretroviral therapy and sexual behaviour changes on HIV epidemiologic trends in Uganda: a modelling study.

Authors:  Leigh Anne Shafer; Rebecca N Nsubuga; Ruth Chapman; Katie O'Brien; Billy N Mayanja; Richard G White
Journal:  Sex Transm Infect       Date:  2014-02-24       Impact factor: 3.519

4.  Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations.

Authors:  Carmen de Mendoza; Ellen Paxinos; Pablo Barreiro; Nuria Camino; Marina Núñez; Vincent Soriano
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

5.  Influence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies.

Authors:  Louis M Mansky; Erwann Le Rouzic; Serge Benichou; Lisa C Gajary
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

6.  Nonlinear observer output-feedback MPC treatment scheduling for HIV.

Authors:  Ryan Zurakowski
Journal:  Biomed Eng Online       Date:  2011-05-27       Impact factor: 2.819

7.  Gag-Specific CD4 and CD8 T-Cell Proliferation in Adolescents and Young Adults with Perinatally Acquired HIV-1 Infection Is Associated with Ethnicity - The ANRS-EP38-IMMIP Study.

Authors:  Jérôme Le Chenadec; Daniel Scott-Algara; Stéphane Blanche; Céline Didier; Thomas Montange; Jean-Paul Viard; Catherine Dollfus; Véronique Avettand-Fenoel; Christine Rouzioux; Josiane Warszawski; Florence Buseyne
Journal:  PLoS One       Date:  2015-12-09       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.